Proinflammatory cytokines and the risk of osteoporotic fractures in postmenopausal breast cancer patients
- 作者: Aleksandrova N.V.1, Sivordova L.E.1, Kurchina E.R.2, Ershov Y.D.2, Krasilnikov A.N.2, Polyakova Y.V.1
-
隶属关系:
- А. Zborovsky Research Institute of Clinical and Experimental Rheumatology
- Volgograd State Medical University
- 期: 卷 28, 编号 3 (2025)
- 页面: 791-796
- 栏目: SHORT COMMUNICATIONS
- URL: https://journal-vniispk.ru/1028-7221/article/view/319936
- DOI: https://doi.org/10.46235/1028-7221-17177-PCA
- ID: 319936
如何引用文章
全文:
详细
Despite the increased risk of bone fractures in patients with malignant neoplasms (MN), especially breast cancer (BC), bone health assessment and preventive treatment of osteoporosis (OP) still remain understudied. The aim of our work was to investigate the significance of systemic inflammatory markers in relation to severity of osteoporotic changes, and to evaluate their association with the estimated 10-year risk of low-energy fractures determined by FRAX in postmenopausal patients with breast cancer. Patients and methods: The study included 85 postmenopausal women with different malignancies, including 40 BC patients. All patients with BC underwent dual-energy X-ray absorptiometry, the 10-year probability of fracture was assessed by FRAX. IL-1β, IL-6, and TNFα were measured by quantitative enzyme-linked immunosorbent assay. The mean time since diagnosis of MN until referral for osteoporosis (OP) was 3 (2.0-4.0) years. In patients with MN, OP was diagnosed in 51.2% of cases, and osteopenia – in 37.2%. In the group of BC patients, osteopenia was documented in 16 patients, OP, in 19 cases. Adjuvant chemotherapy was performed in 42.5% of cases among breast cancer patients, and adjuvant hormonal therapy was performed in 87.5% of cases (different postmenopausal hormone therapies were used). When comparing the cytokine levels in BC subgroups with presence (47.5%) or absence of OP, we have found that IL-1β was higher in patients with OP as compared to both normal persons and osteopenic patients (p = 0.027 and p = 0.029, respectively); IL-6 was higher only in patients with OP compared to normal subjects (p = 0.011); TNFα in OP and osteopenia exceeded those values in OP-free cases (p = 0.001 and p = 0.039, respectively). TNFα levels correlated with the risk score for large osteoporotic fractures (FRAX:MOF) (rS = 0.33, p = 0.036) and IL-6 (rS = 0.55). A higher 10-year risk of vertebral fractures (p = 0.003) was observed in the group of BC patients with ‘high’ (> median) TNFα levels. In summary, proinflammatory cytokines seem to be involved in bone resorption processes. Postmenopausal BC patients have an increased estimated 10-year risk of low-energy spine fractures associated with high TNFα levels.
作者简介
Ninel Aleksandrova
А. Zborovsky Research Institute of Clinical and Experimental Rheumatology
编辑信件的主要联系方式.
Email: nynel68@mail.ru
ORCID iD: 0000-0002-8124-4239
PhD (Medicine), Senior Researcher, Laboratory of Functional Research Methods, Ultrasound Diagnostics and Rehabilitation Therapy
俄罗斯联邦, 76 Zemlyachki St, Bldg 2, Volgograd, 400138Larisa Sivordova
А. Zborovsky Research Institute of Clinical and Experimental Rheumatology
Email: seeword@mail.ru
ORCID iD: 0000-0002-0965-6060
PhD (Medicine), Leading Researcher, Laboratory of Methods of Treatment and Prevention of Joint Diseases
俄罗斯联邦, 76 Zemlyachki St, Bldg 2, Volgograd, 400138Elizaveta Kurchina
Volgograd State Medical University
Email: elizavetakurcina@gmail.com
ORCID iD: 0009-0005-1987-7376
Master’s Student, Department of Hospital Therapy
俄罗斯联邦, VolgogradYaroslav Ershov
Volgograd State Medical University
Email: yaroslav34ru@gmail.com
ORCID iD: 0009-0005-9245-4396
Master’s Student, Department of Hospital Therapy
俄罗斯联邦, VolgogradAndrey Krasilnikov
Volgograd State Medical University
Email: post@volgmed.ru
PhD (Medicine), Associate Professor, Department of Hospital Therapy
俄罗斯联邦, VolgogradYulia Polyakova
А. Zborovsky Research Institute of Clinical and Experimental Rheumatology
Email: jpolyakova@yandex.ru
ORCID iD: 0000-0002-3022-4166
PhD (Medicine), Researcher, Laboratory of Methods of Treatment and Prevention of Joint Diseases
俄罗斯联邦, 76 Zemlyachki St, Bldg 2, Volgograd, 400138参考
- Мерабишвили В.М. Состояние онкологической помощи в России: рак молочной железы среди женского населения. Заболеваемость, смертность, достоверность учета, детальная локализационная и гистологическая структура (популяционное исследование на уровне федерального округа) // Вопросы онкологии, 2022. Т. 68, № 3. С. 286-293. [Merabishvili V.M. The state of oncological care in Russia: breast cancer among the female population. Incidence, mortality, reliability of registration, detailed localization and histological structure (population study at the federal district level). Voprosy onkologii = Issues of Oncology, 2022, Vol. 68, no. 3, pp. 286-293. (In Russ.)]
- Aleksandrov A.V., Aleksandrova N.V. Peculiarities of interaction of chronic inflammation and depression in rheumatoid arthritis. Ann. Rheum. Dis., 2021, Vol. 80, Suppl. 1, 1110. doi: 10.1136/annrheumdis-2021-eular.3087.
- Aleksandrova N.V., Aleksandrov V.A., Zagorodneva E.A., Nikitina N.V., Aleksandrov A.V. Cytokines as potential biomarkers of atherosclerotic vascular lesions in rheumatoid arthritis. Aging Clin. Exp. Res., 2023, Vol. 35, s1, pp. 395-396.
- Di Meglio A., Havas J., Pagliuca M., Franzoi M.A., Soldato D., Chiodi C.K., Gillanders E., Dubuisson F., Camara-Clayette V., Pistilli B., Ribeiro J., Joly F., Cottu P.H., Tredan O., Bertaut A., Ganz P.A., Bower J., Partridge A.H., Martin A.L., Everhard S., Boyault S., Brutin S., André F., Michiels S., Pradon C., Vaz-Luis I. A bio-behavioral model of systemic inflammation at breast cancer diagnosis and fatigue of clinical importance 2 years later. Ann. Oncol., 2024, Vol. 35, no. 11, pp. 1048-1060.
- Goldvaser H., Barnes T.A., Šeruga B., Cescon D.W., Ocaña A., Ribnikar D., Amir E. Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis. J. Nat. Cancer Inst., 2018, Vol. 110, no. 1, pp. 31-39.
- Gulyás K., Horváth Á., Végh E., Pusztai A., Szentpétery Á., Pethö Z., Váncsa A., Bodnár N., Csomor P., Hamar A., Bodoki L., Bhattoa H.P., Juhász B., Nagy Z., Hodosi K., Karosi T., FitzGerald O., Szücs G., Szekanecz Z., Szamosi S., Szántó S. Effects of 1-year anti-TNF-α therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis. Clin. Rheumatol., 2020, Vol. 39, no. 1, pp. 167-175.
- Liang E., Beshara M., Sheng H., Huang X.W., Roh J.M., Laurent C.A., Lee C., Delmerico J., Tang L., Lo J.C., Hong C.C., Ambrosone C.B., Kushi L.H., Kwan M.L., Yao S. A prospective study of vitamin D, proinflammatory cytokines, and risk of fragility fractures in women on aromatase inhibitors for breast cancer. Breast Cancer Res. Treat., 2024, Vol. 208, no. 2, pp. 349-358.
- Nisha Y., Dubashi B., Bobby Z., Sahoo J.P., Kayal S., Ananthakrishnan R., Reddy V.B., Charles L., Ganesan P. Negative impact on bone homeostasis in postmenopausal women with non-metastatic breast cancer during cytotoxic chemotherapy. J. Bone Miner. Metab., 2023, Vol. 41, no. 5, pp. 682-692.
- Pedersini R., Cosentini D., Rinaudo L., Zamparini M., Ulivieri F.M., di Mauro P., Maffezzoni F., Monteverdi S., Vena W., Laini L., Amoroso V., Simoncini E.L., Farina D., Mazziotti G., Berruti A. Assessment of DXA derived bone quality indexes and bone geometry parameters in early breast cancer patients: A single center cross-sectional study. Bone Rep., 2023, Vol. 18, 101654. doi: 10.1016/j.bonr.2023.101654
- Rouach V., Greenman Y., Chodick G., Goldshtein I. DXA assessment and fracture prevention in hormone positive breast cancer patients after treatment initiation with aromatase inhibitors: A registry-based cohort study. J. Bone Oncol., 2023, Vol. 42, 100501. doi: 10.1016/j.jbo.2023.100501.
- Schousboe J.T., Shepherd J.A., Bilezikian J.P., Baim S. Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry. J. Clin. Densitom., 2013, Vol. 16, no. 4, pp. 455-466.
- Ye C., Leslie W.D. Fracture risk and assessment in adults with cancer. Osteoporos. Int., 2023, Vol. 34, no. 3, pp. 449-466.
补充文件
